Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
Modern Rheumatology|December 16, 2014
Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumoniaMichi Tanaka, Ryuji Koike, Ryoko Sakai, et al.
Respiratory Investigation|May 2, 2026
Differences in chest HRCT findings in relation to ANCA subtypes in ANCA-associated vasculitisYusuke Usui, Susumu Sakamoto, Sakae Homma, et al.
Arthritis Research & Therapy|September 25, 2014
Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of miceWaka Yokoyama, Hitoshi Kohsaka, Kayoko Kaneko, et al.
Scientific Reports|December 31, 2024
Associations of gut microbiota with disease development, disease activity, and therapeutic effects in patients with systemic lupus erythematosusJunko Nishio, Hiroshi Sato, Eri Watanabe, et al.
The Journal of Rheumatology|April 19, 2011
Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm SafetyYukiko Komano, Michi Tanaka, Toshihiro Nanki, et al.
Annals of Surgical Oncology|November 19, 2020
New Assay System Elecsys Anti-p53 to Detect Serum Anti-p53 Antibodies in Esophageal Cancer Patients and Colorectal Cancer Patients: Multi-institutional StudySatoshi Yajima, Takashi Suzuki, Yoko Oshima, et al.
Arthritis Research & Therapy|April 17, 2015
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registryRyoko Sakai, Soo-Kyung Cho, Toshihiro Nanki, et al.
Modern Rheumatology|December 11, 2013
A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and JapanSoo-Kyung Cho, Ryoko Sakai, Toshihiro Nanki, et al.
Rheumatology Advances in Practice|November 2, 2020
An open-label, randomized controlled trial of sulfamethoxazole-trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-upMasako Utsunomiya, Hiroaki Dobashi, Toshio Odani, et al.
The Journal of Rheumatology|February 3, 2015
Assessment of risks of pulmonary infection during 12 months following immunosuppressive treatment for active connective tissue diseases: a large-scale prospective cohort studyHayato Yamazaki, Ryoko Sakai, Ryuji Koike, et al.
Pageof 13